A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations

QJM: An International Journal of Medicine

Volumn 101, Issue 8, 2008, Pages 631-641

  Cooper, K ^a   Bryant, J ^a   Picot, J ^a   Clegg, A ^a   Roderick, P R ^b   Rosenberg, W M ^c   Patch, C ^d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IRON;

ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DECISION TREE; DNA DETERMINATION; FAMILY STUDY; HEALTH CARE COST; HEMOCHROMATOSIS; HIGH RISK POPULATION; IRON OVERLOAD; LIVER BIOPSY; PHENOTYPIC VARIATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGENY; SENSITIVITY AND SPECIFICITY; SIBLING; UNITED KINGDOM;

EID: 49149115037     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn070     Document Type: Article

References (26)

1. Jackson HA, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD, et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 2001; 114:474-84.
2. Murphy S, Curran MD, McDougall N, Callender ME, O'Brien CJ, Middleton D. High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population - implications for haemochromatosis. Tissue Antigens 1998; 52:484-8.
3. Bryant J, Cooper K, Picot J, Clegg A, Roderick P, Rosenberg W, et al Diagnostic strategies using DNA testing for hereditary haemochromatosis: A systematic review and economic evaluation. Health Technol Assess 2008 (in press).
4. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis [see comment]. Nat Genet 1996; 13 399-408.
5. British Society for Haematology. British Committee for Standards in Haematology. Guidelines on diagnosis and therapy. Genetic Haemochromatosis. Oxford, Abingdon, 2000.
6. NICE. Guide to the Methods of Technology Appraisal. London, NICE, 2004.
7. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003; 6 9-17.
8. Yen AW, Fancher TL, Bowlus CL. Revisiting hereditary hemochromatosis: current concepts and progress. [Review] [60 fefs]. Am J Med 2006; 119:391-9.
9. Beutler E. Genetic irony beyond haemochromatosis: Clinical effects of HLA-H mutations. Lancet 1997; 349:296-7.
10. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341:718-24.
11. Moodie SJ, Ang L, Stenner JM, Finlayson C, Khotari A, Levin GE, et al Testing for haemochromatosis in a liver clinic population: relationship between ethnic origin, HFE gene mutations, liver histology and serum iron markers [see comment]. Eur J Gastroenterol Hepatol 2002; 14:223-9.
12. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood-donors for hereditary hemochromatosis - decision-analysis model-based on a 30-year database. Gastroenterology 1995; 109:177-88.
13. Vantyghem MC, Fajardy I, Dhondt F, Girardot C, D'Herbomez M, Danze PM, et al. Phenotype and HFE genotype in a population with abnormal iron markers recruited from an Endocrinology Department. Eur J Endocrinol 2006; 154:835-41.
14. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis - a changing scene. Am J Med 1991; 90:445-9.
15. Adams PC, Kertesz AE, Valberg LS. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy. J Clin Gastroenterol 1993; 16:207-10.
16. McCune CA, Ravine D, Carter K, Jackson HA, Hutton D, Hedderich J, et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 2006; 55:554-62.
17. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford, Oxford University Press, 2006.
18. Gilmore I, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36 437-41.
19. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000; 132:261-9.
20. Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: Prevalence and cost-effectiveness. Hepatology 1995; 22:1720-7.
21. Anderson RT, Wenzel L, Walker AP, Ruggiero A, Acton RT, Hall MA, et al. Impact of hemochromatosis screening in patients with indeterminate results: The hemochromatosis and iron overload screening study. Genet Med 2006; 8:681-7.
22. Adams PC. Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis. Clin Genet 1998; 53 176-8.
23. A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium. Gut 1997; 41:841-4.
24. UK Genetic Testing Network. [www.ukgtn.org (accessed May 21 2007)].
25. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation. Health Technol Assess 2006; 10:28.
26. Curtis L, Netten A. Unit Costs of Health and Social Care. [http://www.pssru.ac.uk/uc/uc2005contents.htm (accessed May 21 2007)].